Skip to content
TrialScanner

NCT03195699

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Phase 1CompletedTVRDLead

Registry record

Lead sponsor
Tvardi Therapeutics, Incorporated
Conditions
Breast Cancer; Head and Neck Squamous Cell Carcinoma; Non Small Cell Lung Cancer; Hepatocellular Cancer; Colorectal Cancer
Primary completion
Jun 24, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03195699 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03195699: Oral STAT3 Inhibitor... | TrialScanner